Category: ERS 2021

AstraZeneca Presents Results of Fasenra in P-IIIb PONENTE Study for the Treatment of Asthma at ERS 2021

Shots: The P-IIIb PONENTE study evaluates the safety & efficacy of Fasenra (30mg, SC, q8w) in adult patients with sev. eosinophilic asthma on high-dose ICS + LABA & long-term use of OCS therapy with/out additional asthma controlled Results: 97% of patients maintained a low OCS dose of ≤5mg across blood eosinophil counts @6mos., 3% of […]

United Therapeutics Presents Results of Tyvaso DPI in BREEZE Clinical Study for the Treatment of Pulmonary Arterial Hypertension at ERS 2021

Shots: The BREEZE study evaluates Tyvaso DPI vs nebulized Tyvaso in 51 patients with PAH who were transitioned from Tyvaso to Tyvaso DPI at a corresponding treprostinil dose The results demonstrated safety and tolerance with improvements in 6MWD compared to baseline, improvements in overall satisfaction, PAH Impact & PROs. Additionally, 96% completed 3wks. treatment phase […]